Investigating how LINE-1 retrotransposons affect diseases and normal body functions using specialized antibodies.
Official title: Development of a novel model to study the effects of LINE-1 retrotransposons in disease and normal physiology using nanobodies
Funded at Mercer University Macon · NIH-10953070 · Data updated 2026-11-12
This study is looking at how certain genetic elements called LINE-1 can affect diseases like Alzheimer's and autism, and they're trying to create a new way to target these elements using tiny antibodies, which could help improve treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mercer University Macon NIH-funded |
| Lab location | 1 site (Macon, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $176,238 |
| NIH project number | 1R21GM155785-01 |
| Project ID | NIH-10953070 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with conditions such as Alzheimer's disease, autism spectrum disorder, or other diseases where LINE-1 activity is implicated.
✕Less likely to help
Patients with conditions unrelated to LINE-1 retrotransposons or those not diagnosed with the target diseases may not benefit from this research.
What this research studies
This research focuses on understanding the role of LINE-1 retrotransposons, which are genetic elements that can influence various diseases and normal physiological processes. The team aims to develop a new model using nanobodies, which are small antibodies, to specifically target and reduce the activity of LINE-1 proteins. By isolating these nanobodies, the researchers hope to gain insights into how LINE-1 contributes to conditions like Alzheimer's disease and autism, potentially leading to better treatment strategies. Patients may benefit from advancements in understanding and managing diseases linked to LINE-1 activity.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for diseases associated with LINE-1 retrotransposons.
How similar studies have gone: While the approach of using nanobodies to study LINE-1 is innovative, similar methodologies have shown promise in other areas of genetic research.
Where this research is happening
-
Mercer University Macon
Macon, United States Active
Researchers
- Principal investigator: Cook, Pamela — Mercer University Macon
- Study coordinator: Cook, Pamela
Related research
Other NIH-funded projects on the same topics.
-
Role of a long noncoding RNA in normal biology and kidney cancer
A cancer-related long noncoding RNA called CRNDE is studied to understand how it affects normal body functions and the development of cancer, with a focus on kidney cancer.
-
Using tiny internal antibodies to block LINE‑1 proteins linked to brain diseases
Researchers are creating tiny antibody tools to block LINE‑1 proteins that may play a role in Alzheimer’s and related conditions.
-
Investigating the role of long noncoding RNA in cancer development and progression
This study is looking at how certain molecules called long noncoding RNAs might affect the growth of kidney cancer, specifically renal cell carcinoma, to find new ways to treat it.
-
Using deep learning and Raman spectroscopy for early cancer diagnosis
This study is trying to see if a new deep learning tool using blood samples can help spot early signs of different types of cancer, like colorectal and gastric cancers, in both healthy people and those already diagnosed.
-
Using brain stimulation to improve learning and decision-making
This study is testing if a type of brain stimulation can help healthy adults learn better and make smarter decisions.
-
Using MRI to guide brain stimulation for memory improvement
This study is testing a new way to boost memory by using MRI scans to guide brain stimulation for people with mild cognitive impairment and healthy individuals.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.